The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania (original) (raw)
Related papers
2013
Schizophrenia is a globally prevalent, severe, chronic psychiatric disorder; leading edge research on the treatment of schizophrenia is carried out intensively both in our country and in the rest of the world (1-33). While impairing social functioning and occupational capacity, schizophrenia is an illness with a frequent occurrence of premature death due to its adverse effects on physical health (metabolic syndrome, diabetes mellitus (DM) type II, cardiovascular illness, etc.) and suicide risk (5-7). Antipsychotics have been used in the treatment of schizophrenia since 1952, in which chlorpromazine was used for the first time in the treatment of psychosis. However, impaired insight as well as the low efficacy and serious side effects of these drugs have led to poor adherence among schizophrenic patients (5-8). Both typical and atypical antipsychotics, which have been in use to date, are effective in treating the positive symptoms of schizophrenia whereas the negative symptoms and es...
Asenapine in bipolar I disorder: evidence and place in patient management
Therapeutic advances in chronic disease, 2013
Asenapine is a new second-generation antipsychotic approved in September 2010 by the European Medicines Agency for the treatment of bipolar disorder. It demonstrated significant efficacy compared with placebo in acute mania or mixed episodes as monotherapy or adjunctive therapy to mood stabilizers (lithium or valproate). Early improvement was noted at day 2 and was strongly associated with response and remission at week 3. Asenapine also appeared effective in treating acute mania in older patients with bipolar disorder. Post hoc analyses of asenapine showed efficacy in treating depressive symptoms during manic or mixed episodes compared with placebo. The efficacy of asenapine in patients with acute mania appeared to remain constant during maintenance treatment. Asenapine was reasonably well tolerated, especially with regard to metabolic effects. There were minimal signs of glucose elevation or lipid changes and the risk of weight gain appeared limited. The prolactin elevation was sm...